Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD study of AR882 in healthy male volunteers
NCT04314986Phase 1Completed
- Sponsor
- Arthrosi Therapeutics
- Start
- Jun 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pozdeutinurad in gout and hyperuricemia (5 arms), sponsored by Arthrosi Therapeutics. Primary endpoints: Incidence of adverse events at 22 days, Incidence of abnormal laboratory findings at 22 days and 8 more. Started Jun 2019; status: completed.
02
Drugs
pozdeutinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04314986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314986.